Goldman Sachs Staying On the Sidelines With ViroPharma (VPHM); Starts at Neutral

Goldman Sachs initiates coverage on ViroPharma (NASDAQ: VPHM) with a Neutral rating and $26 price target.

The firm highlights ViroPharma as profitable, mid-cap biotechnology company with three marketed drugs. The key driver is Cinryze for HAE, the firm notes. While the company is an attractive growth story in the mid-cap biotech sector, outstanding questions on expansion of manufacturing capacity and limited pipeline catalysts keeps Goldman on the sidelines.

For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.

Shares of ViroPharma closed at $27.02 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Jefferies Starts Aehr Test Systems (AEHR) at Buy
• JPMorgan Resumes SanDisk (SNDK) at Overweight